Nexelis Marburg GmbH provides assay development, qualification and validation as well as advanced laboratory analyses, particularly to obtain regulatory clinical endpoints in infectious, metabolic diseases and oncology with a focus on immunogenicity and vaccine efficacy (Phase I-IV). The company is based at the Behringwerke site in Marburg and employed on average 81 staff in 2024; employees are remunerated under the chemical industry collective agreement or as non-tariff (AT) employees. Nexelis Marburg has been a 100% subsidiary of IQVIA since January 5, 2022 and belongs within the group to IQVIA Laboratories (formerly Q2 Labsolutions), enabling group-level coordination and joint investments with sites in the USA and Canada. Quality and environmental measures are pronounced: the laboratory was accredited according to GCLP in May 2024, participated in the “My Green Lab” program and received a platinum certificate; in Q4 2024 the first certification stage for ISO 14001/45001 was completed with certification planned for 2025.
Gegenstand des Unternehmens ist das Anbieten von Assay-Entwicklung und Durchführung von hochentwickelten Labortesten in den Bereichen Infektions-, Stoffwechselerkrankungen und Onkologie.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Marburg Local Court, HRB 7875 (as of 9 October 2026)
Source: German Commercial Register (Handelsregister) Marburg Local Court, HRB 7875 (as of 9 October 2026)
Sign in to download data
Source: German Commercial Register (Handelsregister) Marburg Local Court, HRB 7875 (as of 9 October 2026)
Sign in to view detailed salary and cost trends.
